Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The increase in volume is (potentially) either absorption of sellers, getting ready to move higher, or distribution with the ‘manipulators’ holding up the SOXX, so that sell, and sell-short positions are opened (not advice, not a recommendation).
Either way, it looks like something’s about to happen.
Semiconductors SOXX, Daily Close
A new daily high, points probability to the upside; new low, the downside (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Unfortunately, the (mad scientist) graphic at left, is not too far removed from what’s really going on in biotech.
While the S&P, Nasdaq Qs, Gold Miners, Semiconductors, Financials, The HOOD, ORCL, and others, continue to make all-time highs, conspicuously absent is biotech, XBI and IBB.
Now, it appears that quietly, in the background, XBI is reversing to the downside.
Biotech XBI, Daily Close
The up-thrust is there, but is a weak penetration of resistance.
Even so, on the ‘test’, volume contracted by -49.24%, when compared to volume on the upside penetration.
Until proven otherwise, this set-up appears to (currently) be the best short opportunity.
With that said, all other short positions have been closed to focus on biotech.
Leveraged inverse fund LABD is being used at this juncture: Trade LABD-25-10, with stop at the session low (not advice, not a reocmmendiaton).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
If there’s any one interview that details what’s really going on, it’s this, link here.
The 48-mintue Kitco session with Bert Dohmen, is much needed straight talk.
It’s all there:
Official data is fake. Markets will (likely) ‘trap’ bulls with massive gap-down. It’s 1929 (again). Crypto is an illusion. Silver/Gold will correct (temporarily) along with the markets. We’re surrounded by bought off media. The population (masses) don’t think or can’t think.
Adding to that are ideas and sources discussed for years on this site, like ShadowStats having ‘real’ data on unemployment and inflation.
The list goes on.
With all that said, let’s look at one of the sectors (retail brokers), that could be hit hard during a surprise downturn.
Robinhood HOOD, Daily
It’s important to note, price action late Friday, began to pull away from the lows … rising into the close.
Just after that close, the announcement, HOOD made it to the S&P.
Wyckoff said a century ago:
‘Somebody always knows something. That ‘something’ shows up on the tape’
Well, there it is.
Was yesterday (the start of) a blow-off?
Froce Index (thrust) was the largest since the IPO, trading on August 4th, of 2021.
Price action is currently (as of 11:58 a.m., EST) retreating off the highs.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.